文献速递糖尿病

十二指肠内给予奎宁对2型糖尿病男性血浆葡萄糖、血糖调节激素及营养饮料胃排空和能量摄入的剂量相关效应:一项双盲随机交叉研究

Dose-related effects of intraduodenal quinine on plasma glucose, glucoregulatory hormones and gastric emptying of a nutrient drink, and energy intake, in men with type 2 diabetes: a double-blind, randomised, crossover study.
PubMed 文献 · Diabetologia · 2024-12-18

在12例2型糖尿病男性中开展双盲随机交叉研究,分A、B两部分各n=12,分别于营养饮料或自助午餐前30分钟十二指肠内给予对照、盐酸奎宁300 mg或600 mg。奎宁单用无效应;饮后两剂量均显著降低血浆葡萄糖峰值(QHCl-600降低2.8±0.6 mmol/l)并减慢胃排空(均p<0.05;胃排空n=11),QHCl-600而非QHCl-300 modestly刺激GLP-1和C肽(均p<0.05),奎宁不影响能量摄入。

要点

  • 十二指肠内奎宁600 mg降低2型糖尿病男性饮后血糖峰值并减慢胃排空。
  • QHCl-600而非QHCl-300可适度刺激血浆GLP-1和C肽。
  • 奎宁不影响自助午餐能量摄入。

核心结论

  • 在2型糖尿病中,急性十二指肠内给予奎宁显著降低口服碳水化合物后的血浆葡萄糖反应,但不影响能量摄入;这些发现支持奎宁用于降低2型糖尿病餐后血糖水平的潜在用途。

研究设计与样本

  • 双盲、随机、交叉研究,男性2型糖尿病患者(年龄68±5岁;HbA1c 49.0±5.0 mmol/mol [6.7±0.4%];BMI 30±1 kg/m2)分A、B两部分,每部分n=12,各在三个独立场合随机接受对照、盐酸奎宁300 mg(QHCl-300)或600 mg(QHCl-600),于营养饮料(2092 kJ,74 g碳水化合物)(A部分)或标准化自助午餐(B部分)前30分钟经十二指肠内给药;参与者和执行研究程序的研究者均对治疗设盲。
  • A部分在基线、奎宁单用后30分钟及饮料后3小时测量血浆葡萄糖、GLP-1、C肽和胰高血糖素,用13C-乙酸呼气试验测饮料胃排空;B部分量化自助午餐能量摄入。

主要发现

  • 奎宁单用无效应;饮料后两剂量奎宁均显著降低血浆葡萄糖峰值(QHCl-600降低2.8±0.6 mmol/l)并减慢胃排空(均p<0.05;n=12,胃排空n=11)。
  • QHCl-600而非QHCl-300 modestly刺激血浆GLP-1和C肽(均p<0.05)。
  • 奎宁不影响能量摄入。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Quinine, when administered intraduodenally to activate bitter-taste receptors, in a dose of 600 mg, stimulates glucagon-like peptide-1 (GLP-1) and insulin, slows gastric emptying and lowers postprandial glucose in healthy people, with consequent implications for the management of type 2 diabetes; the effect of quinine on energy intake is uncertain. We have investigated the dose-related effects of quinine on postprandial blood glucose levels and energy intake in people with type 2 diabetes. METHODS: Male participants with type 2 diabetes (age: 68±5 years; HbA1c: 49.0±5.0 mmol/mol [6.7±0.4%], BMI: 30±1 kg/m2) received in two study parts (A and B, n=12 each), on three separate occasions each, in randomised, crossover fashion, control, or 300 mg (QHCl-300) or 600 mg (QHCl-600) quinine hydrochloride, intraduodenally 30 min before a nutrient drink (2092 kJ, 74 g carbohydrate) (part A) or a standardised buffet-lunch (part B). Both the participants and investigators performing the study procedures were blinded to the treatments. In part A, plasma glucose, GLP-1, C-peptide and glucagon were measured at baseline, for 30 min after quinine alone and for 3 h post drink. Gastric emptying of the drink was measured with a 13C-acetate breath test. In part B, energy intake from the buffet-lunch was quantified. RESULTS: Quinine alone had no effect. Post drink, both quinine doses reduced peak plasma glucose markedly (QHCl-600 by 2.8±0.6 mmol/l) and slowed gastric emptying (all p<0.05; n=12, except for gastric emptying, n=11). QHCl-600, but not QHCl-300, stimulated plasma GLP-1 and C-peptide modestly (both p<0.05). Quinine did not affect energy intake. CONCLUSIONS/INTERPRETATION: In type 2 diabetes, acute intraduodenal administration of quinine markedly reduces the plasma glucose response to oral carbohydrate, but does not affect energy intake. These findings support the potential use of quinine to reduce postprandial blood glucose levels in type 2 diabetes. TRIAL REGISTRATION: anzctr.org.au ACTRN12620000972921/ACTRN12621000218897 FUNDING: The study was funded by a Diabetes Australia Research Project Grant.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bitarafan V, Anjom-Shoae J, Rezaie P, et al. Dose-related effects of intraduodenal quinine on plasma glucose, glucoregulatory hormones and gastric emptying of a nutrient drink, and energy intake, in men with type 2 diabetes: a double-blind, randomised, crossover study. Diabetologia. 2024. PMID: 39690248. doi:10.1007/s00125-024-06344-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。